Enanta Pharmaceuticals (FRA:9EP) Construction In Progress : €1.11 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Construction In Progress?

Enanta Pharmaceuticals's quarterly construction in progress declined from Sep. 2024 (€20.50 Mil) to Dec. 2024 (€1.22 Mil) and declined from Dec. 2024 (€1.22 Mil) to Mar. 2025 (€1.11 Mil).

Enanta Pharmaceuticals's annual construction in progress declined from Sep. 2022 (€2.58 Mil) to Sep. 2023 (€1.19 Mil) but then increased from Sep. 2023 (€1.19 Mil) to Sep. 2024 (€20.50 Mil).

Enanta Pharmaceuticals Construction In Progress Historical Data

The historical data trend for Enanta Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Construction In Progress Chart

Enanta Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Construction In Progress

Get a 7-Day Free Trial

0.02

2.58

1.19

20.50

Enanta Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Construction In Progress	Get a 7-Day Free Trial															-	13.75	20.50	1.22	1.11

Enanta Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Enanta Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (FRA:9EP) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

ENTA:USA

Address

4 Kingsbury Avenue, Watertown, MA, USA, 02472

Website

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals Headlines

No Headlines